Gene therapy of cancer : translational approaches from preclinical studies to clinical implementation /

Gene therapy of cancer : translational approaches from preclinical studies to clinical implementation /

Saved in:
Bibliographic Details
Imprint:San Diego : Academic Press, ©1999.
Description:xvii, 406 pages, [8] pages of plates : illustrations (some color) ; 29 cm
Language:English
Subject:
Cancer -- Gene therapy.
Gene therapy.
Cancer -- Immunotherapy.
Neoplasms -- therapy.
Genetic Therapy -- methods.
Immunotherapy -- methods.
Neoplasms -- genetics.
Cancer -- Gene therapy.
Cancer -- Immunotherapy.
Gene therapy.
Format: Print Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/3452513
Hidden Bibliographic Details
Other authors / contributors:Lattime, Edmund C., 1951-
Gerson, Stanton L.
ISBN:0124371906
9780124371903
Notes:Includes bibliographical references and index.
Table of Contents:
  • Contributors
  • Preface
  • Part I. Vectors for Gene Therapy of Cancer
  • 1. Retroviral Vector Design for Cancer Gene Therapy
  • I. Introduction
  • II. Applications for Retroviral Vectors in Oncology
  • III. Biology of Retroviruses
  • IV. Principles of Retroviral Vector Systems
  • V. Advances in Retroviral Vector Tailoring
  • VI. Outlook
  • References
  • 2. Noninfectious Gene Transfer and Expression Systems for Cancer Gene Therapy
  • I. Introduction
  • II. Advantages and Disadvantages of Infectious, Viral-Based Vectors for Human Gene Therapy
  • III. Rationale for Considering Noninfectious, Plasmid-Based Expression Systems
  • IV. Gene Transfer Technologies for Plasmid-Based Vectors: Preclinical Models and Clinical Cancer Gene Therapy Trials
  • V. Plasmid Expression Vectors
  • VI. Future Directions
  • References
  • 3. Parvovirus Vectors for the Gene Therapy of Cancer
  • I. Introduction
  • II. Biology of Parvoviridae and Vector Development
  • III. Applications of Recombinant Parvovirus Vectors to Cancer Gene Therapy
  • IV. Perspectives, Problems, and Future Considerations
  • References
  • 4. Antibody-Targeted Gene Therapy
  • I. Introduction
  • II. Background: Monoclonal Antibodies and Cancer Therapy
  • III. Recent Advances: Monoclonal-Antibody-Mediated Targeting and Cancer Gene Therapy
  • IV. Future Directions
  • References
  • 5. Ribozymes in Cancer Gene Therapy
  • I. Introduction
  • II. Ribozyme Structures and Functions
  • III. Cancer Disease Models for Ribozyme Application
  • IV. Challenges and Future Directions
  • References
  • 6. The Advent of Lentiviral Vectors: Prospects for Cancer Therapy
  • I. Introduction
  • II. Structure and Function of Lentiviruses
  • III. Features that Distinguish Lentiviral from Oncoretroviral Vectors
  • IV. Manufacture of Lentiviral Vectors
  • V. Possible Applications of Lentiviral Vectors in Cancer Therapy
  • VI. Conclusions
  • References
  • Part II. Immune Targeted Gene Therapy
  • 7. Immunologic Targets for the Gene Therapy of Cancer
  • I. Introduction
  • II. Cellular (T-Lymphocyte-Mediated) Versus Humoral (Antibody-Mediated) Immune Responses to Tumor Cells
  • III. Response of CD4+ and CD8+ T Lymphocytes to Tumor Antigens Presented in the Context of Molecules Encoded by the Major Histocompatibility Complex
  • IV. Response of Tumor-Bearing Individuals to Tumor Antigens
  • V. Tumor-Associated Peptides as Candidate Targets for Tumor-Specific Lymphocytes
  • VI. Immunotherapeutic Strategies for the Treatment of Cancer
  • VII. Conclusions
  • References
  • Part IIa. Vaccine Strategies
  • 8. Development of Epitope-Specific Immunotherapies for Human Malignancies and Premalignant Lesions Expressing Mutated ras Genes
  • I. Introduction
  • II. Cellular Immune Response and Antigen Recognition
  • III. Pathways of Antigen Processing, Presentation, and Epitope Expression
  • IV. T-Lymphocyte Subsets
  • V. Ras Oncogenes in Neoplastic Development
  • VI. Cellular Immune Responses Induced by ras Oncogene Peptides
  • VII. Identification of Mutant ras CD4+ and CD8+ T-Cell Epitopes Reflecting Codon 12 Mutations
  • VIII. Anti-ras Immune System Interactions: Implications for Tumor Immunity and Tumor Escape
  • IX. Paradigm for Anti-ras Immune System Interactions in Cancer Immunotherapy
  • X. Future Directions
  • References
  • Part IIb. Dendritic Cell-Based Gene Therapy
  • 9. Introduction to Dendritic Cells
  • I. Introduction
  • II. Features of Dendritic Cells
  • III. Dendritic Cell Subsets
  • IV. Functional Heterogeneity of Dendritic Cell Subsets
  • V. Dendritic Cells in Tumor Immunology
  • VI. Dendritic Cells and Gene Therapy
  • VII. Conclusions
  • References
  • 10. DNA and Dendritic Cell-Based Genetic Immunization Against Cancer
  • I. Introduction
  • II. Background
  • III. Recent Advances: Methods of Genetic Immunization
  • IV. Preclinical Development and Translation to the Clinic
  • V. Proposed and Current Clinical Trials
  • VI. Future Directions
  • References
  • 11. RNA-Transfected Dendritic Cells as Immunogens
  • I. Introduction
  • II. Advantages of Loading Dendritic Cells with Genetic Material
  • III. Viral Versus Nonviral Methods of Gene Transfer 200
  • IV. RNA Versus DNA Loading of Dendritic Cells
  • V. RNA Loading of Dendritic Cells
  • VI. Amplification of RNA Used to Load Dendritic Cells
  • VII. Uses of RNA-Loaded Dendritic Cells
  • VIII. Future Directions
  • References
  • Part IIc. Cytokines And Co-Factors
  • 12. In Situ Immune Modulation Using Recombinant Vaccinia Virus Vectors: Preclinical Studies to Clinical Implementation
  • I. Introduction
  • II. Generation of Cell-Mediated Immune Responses
  • III. Cytokine Gene Transfer Studies in Antitumor Immunity
  • IV. In Situ Cytokine Gene Transfer to Enhance Antitumor Immunity
  • V. Future Directions
  • VI. Conclusions
  • References
  • 13. The Use of Particle-Mediated Gene Transfer for Immunotherapy of Cancer
  • I. Introduction
  • II. Background
  • III. Recent Advances
  • IV. Issues Regarding Evaluation in Clinical Trials
  • V. Recent Clinical Trials
  • VI. Potential Novel Uses and Future Directions
  • References
  • Part IId. Genetically Modified Effector Cells For Immune-Based Immunotherapy
  • 14. Applications of Gene Transfer in the Adoptive Immunotherapy of Cancer
  • I. Introduction
  • II. Use of Gene-Modified Tumors to Generate Antitumor-Reactive T Cells
  • III. Genetic Manipulation of T Cells to Enhance Antitumor Reactivity
  • IV. Genetic Modulation of Dendritic Cells
  • V. Summary
  • References
  • 15. Update on the Use of Genetically Modified Hematopoietic Stem Cells for Cancer Therapy
  • I. Introduction
  • II. Human Hematopoietic Stem Cells as Vehicles of Gene Transfer
  • III. Preclinical Studies of Gene Transfer into Hematopoietic Stem Cells
  • IV. Applications of Genetically Manipulated Hematopoietic Stem Cells to the Therapy of Human Cancer
  • V. Conclusions
  • References
  • Part III. Oncogene-Targeted Gene Therapy
  • 16. Clinical Applications of Tumor-Suppressor Gene Therapy
  • I. Introduction
  • II. p53
  • III. BRCA1
  • IV. Onyx-015 Adenoviruses
  • V. Summary and Future Work
  • References
  • 17. Cancer Gene Therapy with Tumor Suppressor Genes Involved in Cell-Cycle Control
  • I. Introduction
  • II. p21WAF1/CIP1
  • III. p16INK4
  • IV. Rb
  • V. p14ARF
  • VI. p27Kip1
  • VII. E2F-1
  • VIII. PTEN
  • IX. BRCA1
  • X. VHL
  • XI. FHIT
  • XII. Apoptosis-Inducing Genes
  • XIII. Conclusions
  • References
  • 18. Cancer Gene Therapy with the p53 Tumor Suppressor Gene
  • I. Introduction
  • II. Vectors for Gene Therapy
  • III. p53
  • IV. Conclusions
  • References
  • 19. Antisense Downregulation of the Apoptosis-Related Bcl-2 and Bcl-xl Proteins: A New Approach to Cancer Therapy
  • I. The Bcl Family of Proteins and their Role in Apoptosis
  • II. Downregulation of Bcl-2 Expression: Antisense Strategies
  • References
  • 20. Gene Therapy for Chronic Myelogenous Leukemia
  • I. Molecular Mechanisms Underlying Ph+ Leukemias
  • II. Therapy
  • III. Gene-Disruption Methods
  • IV. Anti-bcr-abl Targeted Therapies
  • V. Anti-bcr-abl Drug-Resistance Gene Therapy for CML
  • VI. Conclusion
  • References
  • Part IV. Manipulation of Drug Resistance Mechanisms by Gene Therapy
  • 21. Transfer of Drug-Resistance Genes into Hematopoietic Progenitors
  • I. Introduction
  • II. Rationale for Drug-Resistance Gene Therapy
  • III. Methyltransferase-Mediated Drug Resistance
  • IV. Cytidine Deaminase
  • V. Glutathione-S-Transferase
  • VI. Dual-Drug-Resistance Approach
  • VII. Clinical Trials
  • VIII. Conclusion
  • References
  • 22. Multidrug-Resistance Gene Therapy in Hematopoietic Cell Transplantation
  • I. Introduction
  • II. P-Glycoprotein
  • III. Targeting Hematopoietic Progenitor Cells for Genetic Modification
  • IV. Expression of P-Glycoprotein in Murine Hematopoietic Progenitors
  • V. Expression of P-Glycoprotein in Human Hematopoietic Progenitors
  • VI. Results of Early Phase I Studies Using MDR1-Transduced Hematopoietic Cells
  • VII. Overcoming Transduction Inefficiency
  • VIII. MDR1 Gene Transfer into Humans: Recent Progress
  • IX. Implication and Future of MDR1 Gene Therapy in Humans
  • References
  • 23. Development and Application of an Engineered Dihydrofolate Reductase and Cytidine-Deaminase-Based Fusion Genes in Myeloprotection-Based Gene Therapy Strategies
  • I. Introduction
  • II. Fusion Genes
  • III. Development of Clinically Applicable Gene Transfer Approaches
  • IV. Preclinical Evidence for Myeloprotection Strategies
  • V. Clinical Applications of Myeloprotection Strategies
  • VI. Challenges
  • References
  • 24. Protection from Antifolate Toxicity by Expression of Drug-Resistant Dihydrofolate Reductase
  • I. Introduction
  • II. Drug-Resistant Dihydrofolate Reductases
  • III. Protection from Antifolate Toxicity In Vitro
  • IV. Protection from Antifolate Toxicity In Vivo: Retroviral Transduction Studies
  • V. Dihydrofolate Reductase Transgenic Mouse System for In Vivo Drug-Resistance Studies
  • VI. Antitumor Studies in Animals Expressing Drug-Resistant Dihydrofolate Reductase
  • VII. Antifolate-Mediated In Vivo Selection of Hematopoietic Cells Expressing Drug-Resistant Dihydrofolate Reductase
  • VIII. Summary and Future Considerations
  • References
  • 25. A Genomic Approach to the Treatment of Breast Cancer
  • I. Introduction
  • II. Toward a Genomic Approach to Therapy
  • III. The Use of DNA Microarrays to Understand Drug Resistance
  • IV. Effects of Genomic-Based Approaches on the Management of Breast Cancer Patients
  • References
  • Part V. Anti-Aniogenesis and Pro-Apoptotic Gene Therapy
  • 26. Antiangiogenic Gene Therapy
  • I. Introduction
  • II. Angiogenesis and its Role in Tumor Biology
  • III. Antiangiogenic Therapy of Cancer and the Role of Gene Therapy
  • IV. Preclinical Models of Antiangiogenic Gene Therapy
  • V. Inhibiting Proangiogenic Cytokines
  • VI. Endothelial Cell-Specific Gene Delivery
  • VII. Future Directions in Antiangiogenic Gene Therapy
  • References
  • 27. VEGF-Targeted Antiangiogenic Gene Therapy
  • I. Introduction
  • II. Angiogenesis and Tumor Growth
  • III. Gene Therapy for Delivery of Antiangiogenic Factors
  • IV. Antiangiogenic Gene Therapy in the Experimental and Clinical Settings
  • V. Vascular Endothelial Growth Factor and Receptors
  • VI. Vascular Endothelial Growth Factor and Angiogenesis
  • VII. Vascular Endothelial Growth Factor Inhibition by Gene Transfer
  • VIII. Issues Regarding Clinical Translation of Antiangiogenic Gene Therapy
  • IX. Conclusion
  • References
  • 28. Strategies for Combining Gene Therapy with Ionizing Radiation to Improve Antitumor Efficacy
  • I. Introduction
  • II. Strategies Using Gene Therapy to Increase the Efficacy of Radiation Therapy
  • III. Enhancing the Replicative Potential of Antitumor Viruses with Ionizing Radiation
  • IV. Transcriptional Targeting of Gene Therapy with Ionizing Radiation (Genetic Radiotherapy)
  • V. Summary and Future Directions
  • References
  • 29. Virotherapy with Replication-Selective Oncolytic Adenoviruses: A Novel Therapeutic Platform for Cancer
  • I. Introduction
  • II. Attributes of Replication-Selective Adenoviruses for Cancer Treatment
  • III. Biology of Human Adenovirus
  • IV. Mechanisms of Adenovirus-Mediated Cell Killing
  • V. Approaches to Optimizing Tumor-Selective Adenovirus Replication
  • VI. Background: dl1520 (ONYX-015)
  • VII. Clinical Trial Results with Wild-Type Adenovirus: Flawed Study Design
  • VIII. A Novel Staged Approach to Clinical Research with Replication-Selective Viruses: dl1520 (ONYX-015)
  • IX. Results from Clinical Trials with dl1520 (ONYX-015)
  • X. Results from Clinical Trials with dl1520 (ONYX-015): Summary
  • XI. Future Directions
  • XII. Summary
  • References
  • 30. E1A Cancer Gene Therapy
  • I. Introduction
  • II. HER2 Overexpression and E1A-Mediated Antitumor Activity
  • III. Mechanisms of E1A-Mediated Anti-Tumor Activity
  • IV. E1A Gene Therapy: Preclinical Models
  • V. E1A Gene Therapy: Clinical Trials
  • VI. Conclusion
  • References
  • Part VI. Prodrug Activation Strategies for Gene Therapy of Cancer
  • 31. Preemptive and Therapeutic Uses of Suicide Genes for Cancer and Leukemia
  • I. Introduction
  • II. Therapeutic Uses of Suicide Genes
  • III. Preemptive Uses of Suicide Genes in Cancer
  • IV. Creation of Stable Suicide Functions by Combining Suicide Gene Transduction with Endogenous Gene Loss
  • V. Preemptive Uses of Suicide Genes to Control Graft-Versus-Host Disease in Leukemia
  • VI. Future Prospects for Preemptive Use of Suicide Genes
  • References
  • 32. Treatment of Mesothelioma Using Adenoviral-Mediated Delivery of Herpes Simplex Virus Thymidine Kinase Gene in Combination with Ganciclovir
  • I. Introduction
  • II. Clinical Use of HSV-TK in the Treatment of Localized Malignancies
  • III. Challenges and Future Directions
  • References
  • 33. The Use of Suicide Gene Therapy for the Treatment of Malignancies of the Brain
  • I. Introduction
  • II. Retrovirus Vector for HSV-TK
  • III. Adenovirus Vector for HSV-TK
  • IV. Herpes Simplex Virus Vectors Expressing Endogenous HSV-TK
  • V. Promising Preclinical Studies
  • References
  • 34. Case Study of Combined Gene and Radiation Therapy as an Approach in the Treatment of Cancer
  • I. Introduction
  • II. Background of the Field
  • III. Recent Advances in Herpes Simplex Virus-Thymidine Kinase Suicide Gene Therapy
  • IV. Combined Herpes Simplex Virus-Thymidine Kinase Suicide Gene Therapy and Radiotherapy
  • V. Issues Regarding Clinical Trials, Translation into Clinical Use, Preclinical Development, Efficacy, Endpoints, and Gene Expression
  • VI. Potential Novel Uses and Future Directions
  • References
  • Index
The John Crerar Library bookplate

Similar Items